Prima Biomed Announces Japanese Patent Grants for IMP321 in Cancer
Prima BioMed Ltd (NASDAQ: PBMD) announces the granting of patent number 5908210 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the Japanese Patent Office.
This patent relates to Prima's IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima's AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3rd of October 2028.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.